id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-256145-4rcy64y8	Menzies-Gow, Andrew	DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma	2020-10-21		.txt	text/plain	5263	239	44	title: DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma DESTINATION is an ongoing phase 3, multicentre, randomized, double-blind, placebo-controlled, parallelgroup LTE study aiming to evaluate the long-term safety and tolerability of tezepelumab 210 mg administered subcutaneously (SC) every 4 weeks (Q4W) in adults (18-80 years old) and adolescents (12-17 years old) treatment cessation. DESTINATION aims to evaluate the long-term safety, tolerability and efficacy of tezepelumab compared with placebo in patients with severe, uncontrolled asthma who complete the NAVIGATOR or SOURCE predecessor studies and continue dosing for approximately 1 year. DESTINATION is an LTE study that is evaluating the long-term safety and tolerability of tezepelumab versus placebo, with continued dosing for approximately 1 year after patients with severe, uncontrolled asthma complete the phase 3 NAVIGATOR or SOURCE tezepelumab studies.	./cache/cord-256145-4rcy64y8.txt	./txt/cord-256145-4rcy64y8.txt